Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
- Meiji/KM Biologics’ 5-in-1 Vaccine Now Available Ahead of NIP Rollout
March 15, 2024
- Ono, Sibylla Strike Neuroscience Drug Discovery Pact
March 15, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
- Tecentriq Filed for Alveolar Soft Part Sarcoma in Japan: Chugai
March 15, 2024
- High Demand Triggers Shipment Curb for G-Lasta Biosimilars
March 14, 2024
- Takeda Taps Asuka Miyabashira as New Japan Pharma Chief
March 14, 2024
- Novo Gears Up Sustainability Efforts by Recycling Injectors in Japan
March 13, 2024
- Full Resumption of Quake-Hit Santen Plant Delayed into April
March 13, 2024
- Amgen’s Otezla Hits Primary Goal in PIII of Japanese PPP Patients
March 12, 2024
- Towa Develops Analytical Method for Nitrosamine in Antidepressant Duloxetine
March 12, 2024
- Sosei, Boehringer Ingelheim Join Hands in Schizophrenia Treatment
March 12, 2024
- Ono Forges Comprehensive Research Alliance with Harvard
March 12, 2024
- Genmab Files Epkinly for Follicular Lymphoma Grade 1-3A in Japan
March 12, 2024
- Xolair SC Pen Versions Approved in Japan: Novartis
March 11, 2024
- Eisai CEO Confident in Leqembi Uptake, Says 90% of US Hospital Targets to Adopt Med by March-End
March 8, 2024
- Japan Ethical Drug Sales Rise 5.6% in January: Crecon
March 8, 2024
- Keytruda Top-Seller Drug for 5th Straight Month in February: Encise
March 8, 2024
- Japan Generic Makers See Smaller Price Cuts in FY2024: Jiho Survey
March 7, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…